Annual exacerbation rate |
53% reduction (95% CI: 46; 59 %) |
−0.94 (95% CI −1.08; −0.82) |
25% |
0.5 exacerbations |
Number of patients who experience 0 exacerbations annually |
Risk ratio: 1.42 (95% CI 1.30; 1.56) |
16.9%-points (95% CI 12.1; 22.5) |
- |
10%-points |
Average %-reduction in daily dose OCS |
NA |
NA |
0.2 |
2.5-mg prednisolone equivalent |
Percentage of patients who experience ≥50% reduction OCS |
1.61 (95% CI 1.07–2.41) |
20.3%-point (95% CI 2.3; 47.0) |
- |
10%-points |
Percentage of patients who are discontinued OCS |
1.91 (95% CI 0.69; 5.30) |
6.9%-point (95% CI −2.3–32.6) |
- |
5%-points |
Average change in FEV1 |
- |
112.9 ml (95% CI: 82.4; 143.4) |
- |
200 ml |
Percentage of patients who experience an improvement of 200 ml or more |
NA |
NA |
- |
15%-points |
Average change in ACQ |
- |
−0.29 point (95% CI: – 0.36; – 0.23) |
- |
ACQ: 0.5 |
Average change in AQLQ |
- |
0.32 point (95% CI: 0.22; 0.43) |
- |
AQLQ: 0.5 |
Percentage of patients who experience SAE |
0.73 (95% CI: 0.57; 0.92) |
−2.4%-point (95% CI: −0.7; −3.8) |
- |
5%-points |
Percentage of patients dropout |
0.85 (95% CI: 0.69; 1.05) |
−2.3%-point (95% CI: −4.7; 0.7). |
- |
10%-points |